Compare · DXCM vs KIDS
DXCM vs KIDS
Side-by-side comparison of DexCom Inc. (DXCM) and OrthoPediatrics Corp. (KIDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and KIDS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.04B, about 63.4x KIDS ($458.0M).
- Over the past year, DXCM is down 9.9% and KIDS is down 17.6% - DXCM leads by 7.7 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 12 for KIDS).
- DXCM has more recent analyst coverage (25 ratings vs 8 for KIDS).
- Company
- DexCom Inc.
- OrthoPediatrics Corp.
- Price
- $74.63-0.86%
- $18.00+0.87%
- Market cap
- $29.04B
- $458.0M
- 1M return
- +27.54%
- +1.64%
- 1Y return
- -9.89%
- -17.57%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2017
- News (4w)
- 26
- 12
- Recent ratings
- 25
- 8
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest KIDS
- Director Pelizzon David R was granted 11,436 shares, increasing direct ownership by 35% to 44,384 units (SEC Form 4)
- Director Fischer Kelly Laine was granted 11,436 shares, increasing direct ownership by 263% to 15,781 units (SEC Form 4)
- Director Ruf Harold was granted 11,436 shares, increasing direct ownership by 136% to 19,837 units (SEC Form 4)
- Director Hughes Bryan W was granted 11,436 shares, increasing direct ownership by 54% to 32,663 units (SEC Form 4)
- Director Riccitelli Samuel D was granted 11,436 shares, increasing direct ownership by 56% to 31,859 units (SEC Form 4)
- Director Dyer George Sinclair Mitchell was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)
- Director Mcdonald Jimmy Duane was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)
- Director Throdahl Mark C was granted 11,436 shares, increasing direct ownership by 7% to 179,317 units (SEC Form 4)
- President and CEO Bailey David R was granted 119,140 shares, increasing direct ownership by 40% to 417,160 units (SEC Form 4)
- Director Infante (Reynolds) Marie C was granted 11,436 shares, increasing direct ownership by 58% to 31,202 units (SEC Form 4)